Is it safe for a patient to be prescribed duloxetine (SNRI) concurrently with lorazepam (benzodiazepine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 10, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Duloxetine and Lorazepam Combination: Safety Assessment

Direct Answer

Yes, it is safe for a patient to be on duloxetine and lorazepam concurrently—the FDA drug label explicitly states that lorazepam does not affect duloxetine pharmacokinetics, and no contraindication exists for this combination. 1

Pharmacokinetic Evidence

The combination has been specifically studied and found to be safe from a drug interaction perspective:

  • Under steady-state conditions (duloxetine 60 mg every 12 hours and lorazepam 2 mg every 12 hours), the pharmacokinetics of duloxetine were not affected by co-administration. 1
  • Duloxetine is metabolized primarily by CYP1A2 and CYP2D6 enzymes, while benzodiazepines like lorazepam undergo glucuronidation, making clinically significant metabolic interactions unlikely. 1, 2
  • Duloxetine is a moderate inhibitor of CYP2D6 but does not inhibit the pathways relevant to lorazepam metabolism. 1, 3

Pharmacodynamic Considerations

While no pharmacokinetic interaction exists, there are important pharmacodynamic effects to monitor:

  • Duloxetine may enhance the effects of benzodiazepines through additive CNS depression. 4
  • Both medications can cause sedation, dizziness, and somnolence, which may be additive when used together. 2, 5, 6
  • The combination does not carry the same severe risks as seen with olanzapine plus benzodiazepines (where fatalities have been reported with high-dose combinations). 7

Clinical Monitoring Algorithm

When prescribing this combination, monitor for:

  • Excessive sedation or somnolence, particularly during the first 2-4 weeks of concurrent therapy 5, 6
  • Fall risk, especially in elderly patients (≥65 years) who are more susceptible to CNS depressant effects 8
  • Cognitive impairment or psychomotor slowing that could affect driving or operating machinery 4
  • Respiratory depression in patients with underlying pulmonary disease, though this risk is lower than with opioid combinations 8

Important Clinical Context

The CDC guidelines note that benzodiazepines should generally be used cautiously and for short durations, particularly when combined with other CNS-active medications. 8 However, this does not constitute a contraindication to the duloxetine-lorazepam combination specifically.

For chronic pain management, duloxetine is recommended as a first-line agent for conditions like diabetic neuropathy, fibromyalgia, and chronic low back pain, while benzodiazepines are not recommended for chronic pain. 8 If the lorazepam is being used for anxiety rather than pain, this combination may be appropriate during acute phases of treatment.

Common Pitfalls to Avoid

  • Do not abruptly discontinue either medication, as duloxetine is associated with discontinuation syndrome and benzodiazepines carry withdrawal risks. 2, 5
  • Avoid combining duloxetine with potent CYP1A2 inhibitors (like fluvoxamine or ciprofloxacin), which can increase duloxetine levels 6-fold—this is a separate concern from the lorazepam interaction. 1, 3
  • Do not use duloxetine with MAOIs due to risk of serotonin syndrome—allow at least 14 days between discontinuing an MAOI and starting duloxetine. 1
  • Use caution in patients with hepatic impairment or severe renal impairment, as duloxetine clearance is significantly reduced in these populations. 3, 4

Dosing Considerations

  • The optimal therapeutic dose of duloxetine is 60 mg once daily, which has been shown effective for depression, anxiety, and pain conditions. 6
  • Higher doses (up to 120 mg daily) may be used but do not consistently provide additional benefit and increase adverse effects. 5, 6
  • Lorazepam should be used at the lowest effective dose for the shortest duration necessary, particularly in elderly patients. 8

References

Research

Serotonin and Norepinephrine Reuptake Inhibitors.

Handbook of experimental pharmacology, 2019

Research

Safety and adverse event profile of duloxetine.

Expert opinion on drug safety, 2005

Research

Duloxetine: A New Treatment for the Emotional and Physical Symptoms of Depression.

Primary care companion to the Journal of clinical psychiatry, 2003

Guideline

Olanzapine Dosing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What are the considerations for prescribing duloxetine (Cymbalta) to a patient who is a low metabolizer for CYP2D6 (cytochrome P450 2D6) and has low sensitivity for CYP2C (cytochrome P450 2C)?
Is it safe to prescribe duloxetine (a serotonin-norepinephrine reuptake inhibitor) to a patient with CYP2C (cytochrome P450 2C) low sensitivity?
What is the interaction between Duloxetine and Metoclopramide (Reglan)?
Can duloxetine (Cymbalta) cause dizziness in a patient, particularly an older adult with a history of chronic pain or mental health conditions?
Can duloxetine (Cymbalta) be given as needed (PRN)?
What percentage of calamine should an over‑the‑counter calamine lotion contain for a 7‑month‑old infant?
What are the LDL‑cholesterol, non‑HDL cholesterol, and triglyceride targets after myocardial infarction, and what stepwise pharmacologic regimen (high‑intensity statin, ezetimibe, PCSK9 inhibitor) should be used to achieve them?
How is gastroparesis diagnosed on upper endoscopy in an adult with chronic nausea, vomiting of undigested food, early satiety, bloating, and risk factors such as diabetes, prior gastric surgery, neurologic disease, or opioid/anticholinergic use?
How is balanitis diagnosed and what are the appropriate treatment options?
What is the recommended management of an acute seizure in a pregnant woman, including safe drug selection and monitoring?
How should I manage an acute hypercapnic COPD exacerbation with rising arterial PaCO2, specifically regarding BiPAP (bilevel positive airway pressure) initial settings, titration, oxygen targets, and adjunctive therapies?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.